ESCRS - PO413 - Deep Sclerectomy Combined With Phacoemulsification With The Postoperative Topical Use Of Bevacizumab Versus Placebo –Short-Term Follow-Up.

Deep Sclerectomy Combined With Phacoemulsification With The Postoperative Topical Use Of Bevacizumab Versus Placebo –Short-Term Follow-Up.

Published 2022 - 40th Congress of the ESCRS

Reference: PO413 | Type: ESCRS 2022 - Posters | DOI: 10.82333/hdvn-9t87

Authors: Katarzyna Lewczuk* 1 , Joanna Jabłońska 1 , Jacek Rudowicz 1 , Maria Gawronska-Cedro 1 , Karolina Korecka-Skowron 1 , Magdalena Oleszczuk 1 , Marek Rękas 1

1Ophthalmology,Military Institute of Medicine,Warsaw,Poland

Purpose

To compare phacodeepsclerectomy with postoperative topical bevacizumab drops (5mg/mL) (bevacizumab gropup BG) and witout (placebo group PG).

Setting

37 patients with uncontrolled glaucoma and cataract were randomized for BG (23 eyes) or PG (14 eyes).

Methods

Intraocular pressure (IOP) and number of medications (meds) were prospectively evaluated. Standard follow-up examinations were performed on days 1 and 7 and after 1, 3, 6, ,9 and 12months. Complications and postoperative interventions were noted. Elevated IOP (>15mmHg), and/or signs of bleb inflammation or fibrosis were indication for 5-Fluorouracil(5Fu) administration.

Results

Mean observation time was 10,69±3,1 months in BG vs 9,86±3,1 in PG.

Baseline IOP was 16,93±3,3 mmHg in BG and 16,32±3,3mmHg in PG. The mean IOP was lower in PG than in BG (15.17±2,3 vs 16.0 ±2.29mm Hg at 12 months).

Baseline BCVA was 0,52±0,2 in BG and 0,55±0,2 in PG. BCVA in both groups increased (0,77±0,2 vs 0,79±0,2 at 12 months).

After 6-month the average number of anti-glaucoma medications was reduced from 2.39±1,0 (0-4) to 0.14(0-2)(p < 0.001) in BG and from 2,43±1,0(1-4) to 0 (p < 0.001) in PG. At the 12-month follow-up, average number of anti-glaucoma medications was reduced from to 0.05±(p<0.001) in BG and to 0 in PG.

Injections of 5Fu were performed in 12 eyes (52%) in BG and in 10 eyes (71%) in PG.

Conclusions

The use of topical bevacizumab after NPDS with cataract surgery gives similar improvement of BCVA, similar reduction of IOP. The reduction od antiglaucoma medications was better in PG. There was lower frequency of 5Fu usage in BG.